William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working against Charles River in the near term to make the stock ...

Charged with rape, Dr. Derrick Todd allegedly sexually assaulted patients under the guise of legitimate medical exams, ...

Massachusetts State Police and firefighters respond to false report of person falling through the ice on the Charles ...

Charles River and Akron Bio have announced the integration of the latter’s CSS liquid cytokines into the former's Cell ...

At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other ...

Mizuho Securities analyst Ann Hynes has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.Stay Ahead of the ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

A former Massachusetts doctor was indicted by a grand jury Friday on two rape charges, officials said. More than 200 women ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...